<DOC>
	<DOCNO>NCT00818753</DOCNO>
	<brief_summary>To assess whether two dos dabigatran etexilate ( 110 mg twice daily ( b.i.d ) 150 mg twice daily ( b.i.d ) ) compare unfractionated heparin ( UFH ) , addition standard dual antiplatelet regimen , provide sufficient anticoagulation set elective percutaneous coronary intervention ( PCI ) .</brief_summary>
	<brief_title>Randomized , Open Label Study Dabigatran Etexilate Elective Percutaneous Coronary Intervention</brief_title>
	<detailed_description />
	<mesh_term>Dabigatran</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>Inclusion criterion : patient 18 85 year due undergo elective PCI inform consent obtain Exclusion criterion : PCI lesion specific condition class III IV congestive heart failure severe hypertension increase bleed risk thrombolytic therapy within 24 hour precede randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>